Patent · US Active

Anti-IGF antibodies

US11299538B2 · kind B2 · utility

0Cited by

16References

18Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Paul Adam · Wien, AT
Eric Borges · Weitensfeld im Gurktal, AT
Robert Rauchenberger · Martinsried, DE
Gabriela Wochnik-Veltrup · Unterschleißheim, DE

Key dates

Filing date	Dec 5, 2018
Grant date	Apr 12, 2022
Priority date	—
Expiry date	Dec 5, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.